Nanotechnological applications in medicine

Current Opinion in Biotechnology

Volumn 18, Issue 1, 2007, Pages 26-30

  Caruthers, Shelton D ^a,b   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; MEDICINE; NANOTECHNOLOGY; NANOTUBES; SEMICONDUCTOR QUANTUM DOTS;

HIGHLY-EFFECTIVE TARGETED THERAPY; LIPOSOMES; NANOSHELLS; PRECLINICAL APPLICATIONS;

BIOMEDICAL ENGINEERING;

DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; LIPOSOME; MACROGOL; NANOPARTICLE; NANOSHELL; NANOTUBE; PACLITAXEL; QUANTUM DOT;

ATHEROSCLEROSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ECHOGRAPHY; EMULSION; GENOMICS; HEPATITIS; LEUKEMIA; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEOMICS; RETINA MACULA DEGENERATION; REVIEW; SYSTEMATIC REVIEW;

DRUG CARRIERS; HUMANS; MEDICINE; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; QUANTUM DOTS;

EID: 33846867696     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.01.006     Document Type: Review

References (55)

1. Weissleder R. Molecular imaging: exploring the next frontier. Radiology 212 (1999) 609-614
2. Wagner V., Dullaart A., Bock A.K., and Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 24 (2006) 1211-1217. Good review, including commercial activities in nanomedicine.
3. The National Nanotechnology Initiative: Research and development leading to a revolution in technology and industry - supplement to the President's 2007 budget. Edited by National Science and Technology Council Subcommittee on Nanoscale Science, Engineering and Technology; 2006: http://www.nano.gov/NNI_07Budget.pdf.
4. Brower V. Is nanotechnology ready for primetime?. J Natl Cancer Inst 98 (2006) 9-11
5. Jain K.K. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn 3 (2003) 153-161
6. Craighead H. Future lab-on-a-chip technologies for interrogating individual molecules. Nature 442 (2006) 387-393
7. Pettigrew R.I., Fee C.A., and Li K.C. Changes in the world of biomedical research are moving the field of 'personalized medicine' from concept to reality. J Nucl Med 45 (2004) 1427
8. Bremer C., Ntziachristos V., and Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 13 (2003) 231-243
9. Herschman H.R. Molecular imaging: looking at problems, seeing solutions. Science 302 (2003) 605-608
10. Tsien R.Y. Imagining imaging's future. Nat Rev Mol Cell Biol Suppl (2003) SS16-SS21
11. Britz-Cunningham S.H., and Adelstein S.J. Molecular targeting with radionuclides: state of the science. J Nucl Med 44 (2003) 1945-1961
12. Lanza G.M., and Wickline S.A. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Probl Cardiol 28 (2003) 625-653
13. Sakamoto J.H., Smith B.R., Xie B., Rokhlin S.I., Lee S.C., and Ferrari M. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat 4 (2005) 627-636
14. Bergman A. Hepatocyte-specific contrast media for CT. An experimental investigation. Acta Radiol Suppl 411 (1997) 1-27
15. Winter P.M., Shukla H.P., Caruthers S.D., Scott M.J., Fuhrhop R.W., Robertson J.D., Gaffney P.J., Wickline S.A., and Lanza G.M. Molecular imaging of human thrombus with computed tomography. Acad Radiol 12 (2005) 9-13. One of the first CT agents specifically targeted to atherosclerotic plaques.
16. Caruthers S.D., Winter P.M., Wickline S.A., and Lanza G.M. Targeted magnetic resonance imaging contrast agents. Methods Mol Med 124 (2006) 387-400
17. Wickline S.A., and Lanza G.M. Nanotechnology for molecular imaging and targeted therapy. Circulation 107 (2003) 1092-1095
18. Kobayashi H., and Brechbiel M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 57 (2005) 2271-2286
19. Saini S., Edelman R.R., Sharma P., Li W., Mayo-Smith W., Slater G.J., Eisenberg P.J., and Hahn P.F. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR Am J Roentgenol 164 (1995) 1147-1152
20. Weissleder R., Elizondo G., Wittenberg J., Lee A.S., Josephson L., and Brady T.J. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175 (1990) 494-498
21. Ruehm S.G., Corot C., Vogt P., Cristina H., and Debatin J.F. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 9 Suppl 1 (2002) S143-S144
22. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., Patri A.K., Thomas T., Mule J., and Baker Jr. J.R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19 (2002) 1310-1316
23. Svenson S., and Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 57 (2005) 2106-2129
24. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., van der Schaft D.W., Storm G., Koning G.A., Griffioen A.W., and Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19 (2005) 2008-2010
25. Banerjee R. Liposomes: applications in medicine. J Biomater Appl 16 (2001) 3-21
26. Hirsch L.R., Gobin A.M., Lowery A.R., Tam F., Drezek R.A., Halas N.J., and West J.L. Metal nanoshells. Ann Biomed Eng 34 (2006) 15-22
27. Toth E., Bolskar R.D., Borel A., Gonzalez G., Helm L., Merbach A.E., Sitharaman B., and Wilson L.J. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J Am Chem Soc 127 (2005) 799-805
28. Wickline S.A., Neubauer A.M., Winter P., Caruthers S., and Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26 (2006) 435-441
29. Gao X., Yang L., Petros J.A., Marshall F.F., Simons J.W., and Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 16 (2005) 63-72
30. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G., Wu A.M., Gambhir S.S., and Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307 (2005) 538-544
31. Manchester M., and Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev 58 (2006) 1505-1522
32. Shukla R., Thomas T.P., Peters J.L., Desai A.M., Kukowska-Latallo J., Patri A.K., Kotlyar A., and Baker Jr. J.R. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 17 (2006) 1109-1115. Demonstration of in vivo targeting of HER2-positive tumors with PAMAM dendrimers to deliver therapeutic or imaging agents.
33. Schmieder A.H., Winter P.M., Caruthers S.D., Harris T.D., Williams T.A., Allen J.S., Lacy E.K., Zhang H., Scott M.J., Hu G., et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 53 (2005) 621-627
34. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., Lacy E.K., Zhang H., Robertson J.D., Wickline S.A., et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63 (2003) 5838-5843
35. Winter P.M., Morawski A.M., Caruthers S.D., Fuhrhop R.W., Zhang H., Williams T.A., Allen J.S., Lacy E.K., Robertson J.D., Lanza G.M., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
36. 19F nanoparticles. Magn Reson Med 52 (2004) 1255-1262
37. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol 41 (2006) 305-312. Demonstration of multispectral MRI for simultaneous detection and imaging of multiple-targeted nanoparticle agents.
38. Cyrus T., Winter P.M., Caruthers S.D., Wickline S.A., and Lanza G.M. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther 3 (2005) 705-715
39. Farokhzad O.C., and Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58 (2006) 1456-1459
40. Lanza G., Winter P., Cyrus T., Caruthers S., Marsh J., Hughes M., and Wickline S. Nanomedicine opportunities in cardiology. Ann NY Acad Sci 1080 (2006) 451-465
41. Leary S.P., Liu C.Y., and Apuzzo M.L. Toward the emergence of nanoneurosurgery: part III-nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery 58 (2006) 1009-1026 discussion 1009-1026
42. Pison U., Welte T., Giersig M., and Groneberg D.A. Nanomedicine for respiratory diseases. Eur J Pharmacol 533 (2006) 341-350. Good review with basics of nanomedicine.
43. Cattel L., Ceruti M., and Dosio F. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J Chemother 16 Suppl 4 (2004) 94-97
44. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7 (2006) 1041-1053. First nanoparticle-based chemotherapeutic of its kind to receive FDA approval.
45. Tao S.L., and Desai T.A. Microfabricated drug delivery systems: from particles to pores. Adv Drug Deliv Rev 55 (2003) 315-328
46. Lesniak M.S., Langer R., and Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 1 (2001) 210-216
47. Santini Jr. J.T., Cima M.J., and Langer R. A controlled-release microchip. Nature 397 (1999) 335-338
48. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56 (2004) 581-587
49. Majoros I.J., Myc A., Thomas T., Mehta C.B., and Baker Jr. J.R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7 (2006) 572-579
50. Roy I., Ohulchanskyy T.Y., Pudavar H.E., Bergey E.J., Oseroff A.R., Morgan J., Dougherty T.J., and Prasad P.N. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125 (2003) 7860-7865
51. Reddy G.R., Bhojani M.S., McConville P., Moody J., Moffat B.A., Hall D.E., Kim G., Koo Y.E., Woolliscroft M.J., Sugai J.V., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 12 (2006) 6677-6686
52. Kannan R., Rahing V., Cutler C., Pandrapragada R., Katti K.K., Kattumuri V., Robertson J.D., Casteel S.J., Jurisson S., Smith C., et al. Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles. J Am Chem Soc 128 (2006) 11342-11343
53. Veiseh O., Sun C., Gunn J., Kohler N., Gabikian P., Lee D., Bhattarai N., Ellenbogen R., Sze R., Hallahan A., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 5 (2005) 1003-1008
54. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 46 (2005) 1210-1218
55. Winter P.M., Neubauer A.M., Caruthers S.D., Harris T.D., Robertson J.D., Williams T.A., Schmieder A.H., Hu G., Allen J.S., Lacy E.K., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2103-2109. One of the first examples of site-targeted drug delivery with longitudinal image-based monitoring using multifunction nanoparticles.